NZ583377A - Method of eliciting an immune response against pandemic influenza virus - Google Patents

Method of eliciting an immune response against pandemic influenza virus

Info

Publication number
NZ583377A
NZ583377A NZ583377A NZ58337708A NZ583377A NZ 583377 A NZ583377 A NZ 583377A NZ 583377 A NZ583377 A NZ 583377A NZ 58337708 A NZ58337708 A NZ 58337708A NZ 583377 A NZ583377 A NZ 583377A
Authority
NZ
New Zealand
Prior art keywords
eliciting
immune response
influenza virus
response against
pandemic influenza
Prior art date
Application number
NZ583377A
Other languages
English (en)
Inventor
Steve Rockman
Martin Pearse
David Ryan
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of NZ583377A publication Critical patent/NZ583377A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ583377A 2007-10-12 2008-10-09 Method of eliciting an immune response against pandemic influenza virus NZ583377A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97957207P 2007-10-12 2007-10-12
PCT/AU2008/001500 WO2009046497A1 (en) 2007-10-12 2008-10-09 Method of eliciting an immune response against pandemic influenza virus

Publications (1)

Publication Number Publication Date
NZ583377A true NZ583377A (en) 2013-11-29

Family

ID=40548886

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583377A NZ583377A (en) 2007-10-12 2008-10-09 Method of eliciting an immune response against pandemic influenza virus

Country Status (10)

Country Link
US (1) US8999353B2 (https=)
EP (1) EP2195019A4 (https=)
JP (1) JP2011500514A (https=)
KR (1) KR20100082825A (https=)
CN (1) CN101820904A (https=)
AU (1) AU2008310312B2 (https=)
CA (1) CA2700937C (https=)
NZ (1) NZ583377A (https=)
SG (1) SG185294A1 (https=)
WO (1) WO2009046497A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2595653B1 (en) 2010-07-23 2017-06-28 Novavax AB Influenza vaccine
US9524531B2 (en) * 2011-05-09 2016-12-20 Microsoft Technology Licensing, Llc Extensibility features for electronic communications
DK2750683T4 (da) 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323733A1 (en) 1998-04-13 1999-10-21 Michael B. Brenner Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof
ES2572834T3 (es) * 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
NZ518401A (en) * 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
NZ520976A (en) * 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
AU2001251316A1 (en) 2000-04-04 2001-10-15 Antigenics Inc. Isolated and purified nonpeptide antigens from mycobacterium tuberculosis
US20040081654A1 (en) 2000-06-16 2004-04-29 Schryvers Anthony B Use of plant oil-bodies in vaccine delivery systems
GB0021757D0 (en) 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20030190333A1 (en) * 2002-02-04 2003-10-09 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
GB0401239D0 (en) 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions
AU2005244128B2 (en) 2004-05-07 2009-06-25 President And Fellows Of Harvard College Pulmonary malarial vaccine
US20060287263A1 (en) * 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
US20070190072A1 (en) * 2004-09-30 2007-08-16 Csl Limited Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus adjuvant
AR054020A1 (es) * 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
CA2662164A1 (en) * 2006-09-01 2008-03-06 Stirling John Edwards Method of eliciting or inducing an immune response

Also Published As

Publication number Publication date
KR20100082825A (ko) 2010-07-20
AU2008310312B2 (en) 2013-12-19
JP2011500514A (ja) 2011-01-06
CA2700937A1 (en) 2009-04-16
US8999353B2 (en) 2015-04-07
CA2700937C (en) 2017-05-09
EP2195019A4 (en) 2012-02-15
WO2009046497A1 (en) 2009-04-16
US20100291146A1 (en) 2010-11-18
CN101820904A (zh) 2010-09-01
EP2195019A1 (en) 2010-06-16
SG185294A1 (en) 2012-11-29
AU2008310312A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
TW200722101A (en) Novel composition
NZ585674A (en) Vaccination with multiple clades of h5 influenza a virus
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
EP2468296A3 (en) Yeast-based vaccine for inducing an immune response
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
IL200859A (en) Dosage antidote for use in a person with influenza antigen or antigenic drug in combination with auxiliary emulsion oil in water and various related aspects thereof
WO2009128950A3 (en) Deletion mutants of flagellin and methods of use
BRPI0510430A (pt) composições e métodos para vacinação mucosal
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
NO20090062L (no) Influensavaksine
MY169275A (en) Method of immunization against the four serotypes of dengue
BRPI0923448A2 (pt) vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.
EP1984388A4 (en) HPV ANTIGENES, VACCINE COMPOSITIONS AND RELATED METHODS
MX347101B (es) Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
NZ630868A (en) Acellular pertussis vaccine
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112012022939A2 (pt) composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
NZ583377A (en) Method of eliciting an immune response against pandemic influenza virus
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2010129947A3 (en) Alpha thymosin peptides as vaccine enhancers
WO2008034121A3 (en) Parasite vaccine
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
WO2008091398A3 (en) Jc virus vaccine

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 OCT 2015 BY DAVIES COLLISON CAVE

Effective date: 20140306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2016 BY LEA SKYLLERSTEDT

Effective date: 20150923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2017 BY LEA SKYLLERSTEDT

Effective date: 20160928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2018 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20170928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20180929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2020 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20190917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2021 BY CPA GLOBAL

Effective date: 20200903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2022 BY CPA GLOBAL

Effective date: 20210902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2023 BY CPA GLOBAL

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2024 BY CPA GLOBAL

Effective date: 20230831

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250904